实时超声造影和融合影像导航下微波消融治疗小肝癌的疗效

doi:10.3760/cma.j.issn.1007-1245.2024.09.019

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (9): 1494-1497.DOI: 10.3760/cma.j.issn.1007-1245.2024.09.019

实时超声造影和融合影像导航下微波消融治疗小肝癌的疗效

王君芳陈娇

黄石市中心医院湖北理工学院附属医院超声科，黄石　435000

收稿日期:2023-12-11 出版日期:2024-05-01 发布日期:2024-05-30
通讯作者: 陈娇，Email：18162921928@163.com
基金资助:
湖北省自然科学基金（2019CFB325）

Microwave ablation guided by real-time contrast-enhanced ultrasound and fusion image in treatment of patients with small liver cancer

Wang Junfang, Chen Jiao

Department of Ultrasound, Huangshi Central Hospital, Hospital Affiliated to Hubei Polytechnic University, Huangshi 435000, China

Received:2023-12-11 Online:2024-05-01 Published:2024-05-30
Contact: Chen Jiao, Email: 18162921928@163.com
Supported by:
Hubei Natural Science Foundation (2019CFB325)

摘要/Abstract

摘要：

目的　探讨应用实时超声造影和融合影像导航下微波消融治疗小肝癌的临床价值。方法　将2019年5月至2020年11月黄石市中心医院收治的84例小肝癌患者纳入研究样本，根据治疗方式分为观察组（实时超声造影和融合影像导航下微波消融）及对照组（手术治疗）。观察组42例中，男23例，女19例，年龄（44.86±3.46）岁，病灶数58个，病灶长径（1.56±1.07）cm；对照组42例，男25例，女13例，年龄（43.60±3.50）岁，病灶数61个，病灶长径（1.62±1.02）cm。比较两组手术时间、住院时间、并发症发生情况；随访截止至2022年11月，比较两组患者病情进展程度、2年内存活及死亡情况。采用t检验、χ²检验、Log-rank检验进行统计分析。结果　观察组手术时间为（92.37±19.43）min、住院时间为（4.37±2.26）d，对照组分别为（142.16±21.83）min、（9.42±2.81）d，两组比较，差异均有统计学意义（t=11.041、9.076，均P<0.001）。观察组并发症总发生率为9.52%（4/42），低于对照组的26.19%（11/42），两组比较差异有统计学意义（χ²=3.977，P=0.046）。观察组局部进展发生率、病死率、2年累积生存率分别为35.71%（15/42）、28.57%（12/42）、70.00%（28/40），对照组分别为33.33%（14/42）、30.95%（13/42）、68.29%（28/41），差异均无统计学意义（χ²=0.054、0.067，Log-rank=0.084，均P>0.05）。结论　应用实时超声造影和融合影像导航下微波消融对治疗小肝癌具有重要临床价值，且手术具有创伤小、安全性高等优点。

关键词:

小肝癌, 微波消融, 超声造影, 融合影像

Abstract:

Objective　To study the value of microwave ablation guided by real-time contrast-enhanced ultrasound and fusion image in the treatment of patients with small liver cancer. Methods　A total of 84 patients with small liver cancer admitted to Huangshi Central Hospital from May 2019 to November 2020 were selected as the study samples. According to the treatment methods, they were divided into an observation group, taking microwave ablation guided by real-time contrast ultrasound and fusion image, and a control group, taking surgical treatment, with 42 cases each group. There were 23 males and 19 females in the observation group; they were (44.86±3.46) years old; there were 58 lesions; the longest lesion diameter was (1.56±1.07) cm. There were 25 males and 17 females in the control group; they were (43.60±3.50) years old; there were 61 lesions; the longest lesion diameter was (1.62±1.02) cm. The operation times, hospitalization times, and incidences of complications were compared between the two groups. The patients were followed up until November 2022. The disease progress and survival and death within 2 years were compared between the two groups. t, χ², and Log-rank tests were applied. Results　The operation time and hospitalization time in the observation group were shorter than those in the control group [(92.37±19.43) min vs. (142.16±21.83) min and (4.37±2.26) d vs. (9.42±2.81) d], with statistical differences between the two groups (t=11.041 and 9.076; both P<0.001). The total incidence of complications in the observation group was lower than that in the control group [9.52% (4/42) vs. 26.19% (11/42); χ²=3.977; P=0.046]. The local progression rate, mortality rate, and 2-year cumulative survival rate of the observation group were 35.71% (15/42), 28.57% (12/42), and 70.00% (28/40), respectively; and those of the control group were 33.33% (14/42), 30.95% (13/42), and 68.29% (28/41), respectively; there were no statistical differences (χ²=0.054 and 0.067; Log-rank=0.084; all P>0.05). Conclusion　Microwave ablation guided by real-time contrast-enhanced ultrasound and fusion image in the treatment of patients with small liver cancer is of great clinical value, minimally invasive, and safe.

Key words:

Small liver cancer, Microwave ablation, Contrast-enhanced ultrasound, Fusion image

王君芳陈娇.

实时超声造影和融合影像导航下微波消融治疗小肝癌的疗效 [J]. 国际医药卫生导报, 2024, 30(9): 1494-1497.

Wang Junfang, Chen Jiao.

Microwave ablation guided by real-time contrast-enhanced ultrasound and fusion image in treatment of patients with small liver cancer [J]. International Medicine and Health Guidance News, 2024, 30(9): 1494-1497.

参考文献

[1] 柳昂,顾玉明,鹿皎. TACE联合微波消融治疗肝尾状叶肿瘤1例[J]. 介入放射学杂志,2018,27(6):590-591. DOI:10.3969/j.issn.1008-794X.2018.06.022.
[2] 张丹,李曾,柏艳红,等. 超声引导下激光与射频消融治疗小肝癌的临床疗效差异[J]. 肝脏,2019,24(6):666-669. DOI:10.3969/j.issn.1008-1704.2019.06.027.
[3] 周小郁,黄光亮,叶洁仪,等. 三维超声造影融合成像评估肝癌射频消融安全边界的价值[J]. 中华超声影像学杂志,2019,28(2):104-108. DOI:10.3760/cma.j.issn.1004-4477. 2019.02.003.
[4] Bo XW, Xu HX, Guo LH, et al. Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment CECT/CEMRI after radiofrequency ablation for liver cancers[J]. Br J Radiol, 2017,90(1078):20170063. DOI: 10.1259/bjr.20170063.
[5] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等. 原发性肝癌规范化病理诊断指南(2015年版)[J]. 中华肝胆外科杂志,2015,21(3):145-151. DOI:10.3760/cma.j.issn.1007-8118. 2015.03.001.
[6] 孙小英,李敬芳,李中. 新型血清肿瘤标志物Egfl7联合AFP在肝细胞癌早期诊断的价值[J]. 肝脏,2018,23(5):405-407. DOI:10.3969/j.issn.1008-1704.2018.05.013.
[7] 赵勤显,于杰,董立男,等. 三维可视化辅助经皮微波消融治疗复发性肝癌价值分析[J]. 中国实用外科杂志,2019,39(10):1068-1070,1076. DOI:10.19538/j.cjps.issn1005-2208.2019.10.18.
[8] Cheng Z, Liang P, Yu X, et al. Percutaneous microwave ablation for benign focal liver lesions: Initial clinical results[J]. Oncol Lett, 2017,13(1):429-434. DOI: 10.3892/ol.2016.5409.
[9] 龙颖琳,李凯,郑荣琴,等. 超声单模态融合成像技术在肝肿瘤热消融术中即时疗效评估中的初步应用[J]. 中华超声影像学杂志,2017,26(4):306-310. DOI:10.3760/cma.j.issn.1004-4477.2017.04.007.
[10] 曹佳颖,毛枫,范培丽,等. 动态三维超声造影定量分析对裸鼠皮下种植瘤不全微波消融的疗效评估[J]. 中华超声影像学杂志,2018,27(6):529-534. DOI:10.3760/cma.j.issn. 1004-4477.2018.06.017.
[11] 徐倩,林淑芝,董士佳,等. 实时影像融合虚拟导航联合CEUS引导射频消融治疗肝癌新生或复发病灶[J]. 中国医学影像技术,2018,34(5):701-704. DOI:10.13929/j.1003- 3289.201710135.
[12] Li K, Su Z, Xu E, et al. Evaluation of the ablation margin of hepatocellular carcinoma using CEUS-CT/MR image fusion in a phantom model and in patients[J]. BMC Cancer, 2017,17(1):61. DOI: 10.1186/s12885- 017-3061-7.
[13] 赵金哲,王娟,沐勇杰,等. 肝癌微波消融中热损伤参数分析[J]. 北京生物医学工程,2019,38(4):392-399,423. DOI:10.3969/j.issn.1002-3208.2019.04.009.
[14] 薛建章,陈良峰,廖凌峰,等. 肝动脉栓塞化疗联合冷循环微波消融治疗肝癌的临床疗效观察[J]. 中华物理医学与康复杂志,2019,41(6):458-460. DOI:10.3760/cma.j.issn. 0254-1424.2019.06.015.
[15] 别志欣,李元明,李彬,等. CT引导下经皮穿刺微波消融治疗老年早期非小细胞肺癌的疗效和安全性[J]. 中华老年医学杂志,2019,38(7):722-726. DOI:10.3760/cma.j.issn.0254-9026.2019.07.003.
[16] 王俊东,魏达友,吴绍锋,等. 超声新技术辅助特殊部位小肝癌微波消融与手术切除的疗效对比研究[J]. 中国超声医学杂志,2019,35(6):506-510. DOI:10.3969/j.issn.1002- 0101.2019.06.009.

实时超声造影和融合影像导航下微波消融治疗小肝癌的疗效

Microwave ablation guided by real-time contrast-enhanced ultrasound and fusion image in treatment of patients with small liver cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

[1]	路晓雯刘梓洋. 增强CT联合超声造影在HCC患者TACE疗效评估中的应用 [J]. 国际医药卫生导报, 2024, 30(5): 754-758.
[2]	韩伟梁伟翔刘韬李若兰. 超声在诊断甲状腺乳头状癌被膜外侵犯中的研究进展 [J]. 国际医药卫生导报, 2023, 29(8): 1037-1040.
[3]	王文君王守忠孔海燕杨文静. 微波消融与射频消融治疗非小细胞肺癌的疗效及癌性疼痛控制研究 [J]. 国际医药卫生导报, 2023, 29(8): 1062-1067.